For example, KRas activation upregulated the eIF5A level, which promoted PC cells' motility and metastasis via Rho/ROCK [16]; cyclic AMP could decrease the RhoA level and inhibited PC cell migration and invasion [17]; and crizotinib, a MET antibody, could downregulate the RhoA level and suppress PC cell invasiveness [18]. The gene discussed is RHOA; the disease is pachyonychia congenita.